An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
A Post-marketing Observational Study for ABBV-951 in Patients Diagnosed With Advanced Parkinson's Disease (aPD)
AbbVie
250 participants
Nov 30, 2023
OBSERVATIONAL
Conditions
Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting. ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan. Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Eligibility
Inclusion Criteria3
- Diagnosed with advanced Parkinson's disease (aPD).
- Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD.
- Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study.
Exclusion Criteria2
- Prior treatment with ABBV-951 for PD.
- Currently participating in interventional clinical trials.
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05916157